Skip to main content
SpringerLink
Log in

From Norway to Novartis: cyclosporin from Tolypocladium inflatum in an open access bioprospecting regime

  • Published:
Biodiversity & Conservation Aims and scope Submit manuscript

Abstract

The Convention on Biological Diversity (CBD) introduces a new regime of source countries' national sovereignty over genetic resources, in which benefit sharing is a central factor. This article shows how Tolypocladium inflatum was collected in Norway in 1969 within an open access regime implying that there is no benefit sharing with the source country from Novartis' present sales of the derived medicines based on cyclosporin. We estimate source country's loss of benefits in comparison with present norms and expectations concerning bioprospecting. Two percent annual royalties would have been a reasonable claim in this case, and in 1997 this amounted to US$ 24.3 million. Such benefits could, for instance, have been targeted to conservation, scientific capacity building and health care. The study provides an indication of possible gains for source countries – countries with developed as well as developing economies – in a case of the finding of a blockbuster drug. Institutional prerequisites for benefit sharing are discussed, and the emphasis, which often is placed on the role of patents as the cause of lack of source country benefits, is in this case found to be misleading.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anon. (1997) Healthcare products top Novartis' growth agenda. European Chemical News, March

  • Anon. (1998a) Novartis puts in a strong first year performance. European Chemical News, February

  • Anon. (1998b) Bioprospecting – temperate fungi tapped for drugs. Chemistry & Industry 6(16) March

  • Aylward BA (1993) The Economic Value of Pharmaceutical Prospecting and its Role in Biodiversity Conservation. London Environmental Economics Centre, London. Discussion Paper DP 93–05, IIED

    Google Scholar 

  • Baath E and Söderström B (1979) Mikrosvamper i svenska barskogsjordar. Svensk Bot. Tidskr. 72: 343–349

    Google Scholar 

  • Baker JT, Borris RP, Carte B, Cordell GA, Soejarto DD, Cragg GM, Gupta MP, Iwu MM, Madulid DR and Tyler VE (1995) Natural product drug discovery and development – new perspectives on international collaboration. Journal of Natural Products – Lloydia 58(9): 1325–1357

    Google Scholar 

  • Balakrishnan K and Pandey A (1996) The panorama of cyclosporin research. Journal of Basic Microbiology 36(2): 121–147

    Google Scholar 

  • Bell J (1997) Biopiracy's latest disguises. Seedling (The Quarterly Newsletter of Genetic Resources Action International) 14(2)

  • Bisset J (1983) Notes on Tolypocladium and related genera. Canadian Journal of Botany 61: 1311–1329

    Google Scholar 

  • Bisset J and Parkinson D (1979) The distribution of fungi in some alpine soils. Canadian Journal of Botany 57: 1609–1629

    Google Scholar 

  • Borel JF and Kis ZL (1991) The discovery and development of cyclosporine (Sandimmune). Transplantation Proceedings 23(2): 1867–1874

    Google Scholar 

  • Borel JF, Feurer C, Gubler HU and Stähelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents and Actions 6(4): 468–475

    Google Scholar 

  • Borel JF, Feurer C, Magnee C and Stähelin HF (1977) Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32: 1017–1025

    Google Scholar 

  • Brown K and Moran D (1994) Valuing biodiversity: the scope and limitations of economic analysis. In: Sánchez V and Juma C (eds) Biodiplomacy. Genetic Resources and International Relations, pp 213–232. ACTS Press, Nairobi

    Google Scholar 

  • Chapela IH (1997) Using fungi from a node of biodiversity: conservation and property rights in Oaxacan forests. In: Hoagland KE and Rossman AY (eds) Global Genetic Resources: Access, Ownership, and Intellectual Property Rights, pp 165–180. Association of Systematics Collections, Washington DC

    Google Scholar 

  • Coleman JS (1990) Foundations of Social Theory. The Belknap Press of Harvard University Press, Cambridge, Mass

    Google Scholar 

  • Cunningham AB (1993) Ethics, Ethnobotanical Research, and Biodiversity. WWF International, Gland

    Google Scholar 

  • DiMasi JA, Hansen RW, Grabowski HG and Lasagna L (1991) Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10: 107–142

    Google Scholar 

  • Dorey E (1998) Roche deCODEs Icelandic population in $ 200 million deal. Nature Biotechnology 16, March

  • Dreyfuss MM and Gams W (1994) Proposal to reject Pachybasium niveum Rostr. in order to retain the name Tolypocladium inflatum W. Gams for the fungus that produces cyclosporin. Taxon 43: 660–661

    Google Scholar 

  • Eisner T (1989) Prospecting for nature's chemical riches. Issues in Science and Technology 6(2): 31–34

    Google Scholar 

  • Eisner T (1991) Chemical prospecting: a proposal for action. In: Bormann FH and Kellert SR (eds) Ecology, Economics, and Ethics: The Broken Circle, pp 196–202. Yale University Press, New Haven

    Google Scholar 

  • Fenwick S (1998) Bioprospecting or biopiracy? Drug Discovery Today 3(9): 399–402

    Google Scholar 

  • Fowler C (1994) Unnatural Selection. Technology, Politics, and Plant Evolution. Gordon and Breach, Yverdon

    Google Scholar 

  • Frey HP (1998) Letter to H. Svarstad. 26 March 1998

  • Gjersvik C (1998) Opplysninger om Novartis og Sandimmun Neoral. Letter to H. Svarstad. 17 March 98

  • Glowka L (1998) A Guide to Designing Legal Frameworks to Determine Access to Genetic Resources. IUCN, Gland, Cambridge, Bonn

    Google Scholar 

  • Haller M (1992) The Sandimmum ‘whodunit’. Article series in Die Weltwoche, 3, 10 and 17 December. Translation by F. Niklaus

  • Härri E and Ruegger A (1977) Organic Compounds. United States Patent No. 4,117,118. Filed: 28 March 1977. Issued: 26 September 1978

  • Harvard Business School (1992) INBio/Merck Agreement: Pioneers in Sustainable Development. Harvard Business School, Boston

    Google Scholar 

  • Hawksworth DL (1997) Fungi and international biodiversity initiatives. Biodiversity and Conservation 6(5): 661–668

    Google Scholar 

  • Hooper D, Hawksworth D and Dhillion S (1995) Microbial diversity and ecosystem processes. Section 6, biodiversity and ecosystem functioning: ecosystem analyses. In: Heywood VH (ed) Global Biodiversity Assessment, pp 433–443. Cambridge University Press, Cambridge

    Google Scholar 

  • Høyland K and Ryvarden L (1990) Er det liv er det sopp. Sopp i miljø og kulturhistorie. Fungiflora, Oslo

    Google Scholar 

  • Iwu MM (1995) An African perspective. In: Baker JT et al. Natural product drug discovery and development – new perspectives on international collaboration. Journal of Natural Products – Lloydia 58(9): 1325–1357

    Google Scholar 

  • Juma C (1989) The Gene Hunters. Biotechnology and the Scramble for Seeds. Zed Books; London Princeton University Press, Princeton

    Google Scholar 

  • Juma C and Sánchez V (1994) Conclusion. In: Sánchez V and Juma C (eds) Biodiplomacy. Genetic Resources and International Relations, pp 311–323. ACTS Press, Nairobi

    Google Scholar 

  • Kloppenburg JR Jr (1988) First the Seed. The Political Economy of Plant Biotechnology, 1492–2000. Cambridge University Press, Cambridge

    Google Scholar 

  • Koester V and Prip C (1993) Legal questions concerning the implementation of Article 15 paragraph five of the Convention on Biological Diversity. Paper presented at the International Conference on the Convention on Biological Diversity: National Interests and Global Imperatives. African Centre for Technology Studies, Nairobi

    Google Scholar 

  • Krattiger AF and Lesser WH (1995) The ‘Facilitator’: proposing a new mechanism to strengthen the equitable and sustainable use of biodiversity. Environmental Conservation 22(3): 211–215

    Google Scholar 

  • Laird SA (1993) Contracts for biodiversity prospecting. In: Reid WV, Laird SA, Meyer CA, Gámez R, Sittenfeld A, Janzen DH, Gollin MA and Juma C (eds) Biodiversity Prospecting: Using Genetic Resources for Sustainable Development, pp 99–130. World Resources Institute, USA

    Google Scholar 

  • Laird SA and Ten Kate K (1999) Natural products and the pharmaceutical industry. In: ten Kate K and Laird SA (eds) Commercial Use of Biodiversity, pp 34–77. Earthscan, London

    Google Scholar 

  • Mateo N (2000) Bioprospecting and conservation in Costa Rica. In: Svarstad H and Dhillion SS (eds) Responding to Bioprospecting: From Biodiversity in the South to Medicines in the North, pp 45–56. Spartacus, Oslo

    Google Scholar 

  • McChesney JD (1996) Biological diversity, chemical diversity, and the search for new pharmaceuticals. In: Balick MJ, Elisabetsky E and Laird SA (eds) Medicinal Resources of the Tropical Forest. Biodiversity and Its Importance to Human Health, pp 11–18. Columbia University Press, New York

    Google Scholar 

  • Morley J, Rummelt A and List M (1994) Ciclosporin Form for Pulmonary Administration. United States Patent No. 5,719,123. Filed: 6 June 1994. Issued: 17 February, 1998

  • Mugabe J, Barber CV, Henne G, Glowka L and La Viña A (1997) Managing access to genetic resources. In: Mugabe J, Barber CV, Henne G, Lyle G and La Viña (eds) Access to Genetic Resources: Strategies for Sharing Benefits, pp 5–32. ACTS Press, Nairobi

    Google Scholar 

  • Munkejord M (1998) Fra høyfjells-sopp til menneskegener. Folkevett 20(4): 5

    Google Scholar 

  • Novartis (1997) Report of the Novartis Foundation for Sustainable Development. 1997/1998

  • Novartis (1998) Operational Review 1997

  • Novartis – [online] (April 1998) URL: http://www.novartis.com/

  • Novartis Foundation – [online] (April 1998) URL: http://www.foundation.novartis.com

  • Novartis Pharma AG – [online] (March 1998) Transplant Square. URL: http://www.transplantsquare. com/index.htm

  • Principe PP (1996) Monetizing the pharmacological benefits of plants. In: Balick MJ, Elisabetsky E and Laird SA (eds) Medicinal Resources of the Tropical Forest. Biodiversity and Its Importance to Human Health, pp 11–18. Columbia University Press, New York

    Google Scholar 

  • RAFI (1994) Conserving Indigenous Knowledge: Integrating Two Systems of Innovation. Rural Advancement Foundation International. Commissioned by the United Nations Development Programme, New York

  • RAFI (1995) Biopiracy Update. RAFI Communique, December 1996. Rural Advancement Foundation International

  • Rehácek Z (1995) The cyclosporins. Folia Microbiology 40(1): 68–88

    Google Scholar 

  • Reid WV (1993–1994) The Economic Realities of Biodiversity. Issues in Science and Technology, Winter

  • Reid WV (1997) Technological change and regulation of access to genetic resources. In: Mugabe J, Barber CV, Henne G, Lyle G and La Viña (eds) Access to Genetic Resources: Strategies for Sharing Benefits, pp 53–70. ACTS Press, Nairobi

    Google Scholar 

  • Reid WV, Laird SA, Meyer CA, Gámez R, Sittenfeld A, Janzen DH, Gollin MA and Juma C (eds) (1993) A new lease on life. In: Biodiversity Prospecting: Using Genetic Resources for Sustainable Development, pp 1–52. World Resources Institute, USA

  • Sandoz Pharma (1994) Biodiversity Prospecting – Sandoz Pharma Policy Statement. Sandoz Press Office, Basel

    Google Scholar 

  • Shand H (1993) A landmark year for biodiversity or bio-piracy? Biotechnology and Development Monitor 17: 24

    Google Scholar 

  • Shiva V (1995) Captive Minds Captive Lives. Ethics, Ecology and Patents on Life. Research Foundation for Science, Technology and Natural Resource Policy, Dehra Dun

    Google Scholar 

  • Shiva V (1997) Biopiracy: The Plunder of Nature and Knowledge. South End Press, Boston, Mass

    Google Scholar 

  • Simpson RD (1997) Biodiversity Prospecting. Shopping the Wilds Is Not the Key to Conservation. Resources. Winter 1997/Issue 126

  • Simpson RD, Sedjo RA and Reid JW (1996) Valuing biodiversity for use in pharmaceutical research. Journal of Political Economy 104: 163–185

    Google Scholar 

  • Stähelin HF (1996) The history of cyclosporin A (Samdimmune) revisited: another point of view. Experientia 52: 12–23

    Google Scholar 

  • Svarstad H (1994) National sovereignty and genetic resources. In: Sánchez V and Juma C (eds) Biodiplomacy. Genetic Resources and International Relations, pp 45–65. ACTS Press, Nairobi

    Google Scholar 

  • Svarstad H (1998) Biologisk mangfold: ressurser i Sør og interesser i Nord. In: Benjaminsen TA and Svarstad H (eds) Samfunnsperspektiver på miljø og utvikling, pp 164–188. Tano Aschehoug, Oslo

    Google Scholar 

  • Svarstad H (2000) Reciprocity, biopiracy, heroes, villains and victims. In: Svarstad H and Dhillion SS (eds) Responding to Bioprospecting: From Biodiversity in the South to Medicines in the North. Spartacus, Oslo

    Google Scholar 

  • Ten Kate K (1995) Biopiracy or Green Petroleum? xpectations & Best Practice in Bioprospecting. Overseas Development Administration, London

    Google Scholar 

  • Ten Kate K, Touche L and Collis A (1998) Yellowstone National Park and the Diversa Corporation. Benefit-Sharing Case Study. Royal Botanic Gardens, Kew, London

    Google Scholar 

  • Thali M (1995) Cyclosporins: immunosuppressive drugs with anti-HIV-1 activity. Molecular Medicine Today 1(1): 287–291

    Google Scholar 

  • Tribe HT (1998) The Discovery and Development of Cyclosporin 12(1), February

  • UNEP (1992) Convention on Biological Diversity. United Nations Environmental Program, Nairobi

    Google Scholar 

  • Watling R and Hawksworth DL (1997) Fungal biodiversity: a British mycological society symposium. (Guest editorial) Biodiversity and Conservation 6(5): 659

    Google Scholar 

  • Webster J (1997) Fungal biodiversity. (Foreword) Biodiversity and Conservation 6(5): 657

    Google Scholar 

  • White M, Pelletier GB, Tan A, Jesina C and Carrier M (1997) Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine Sandimmune versus the microemulsion neoral in heart transplant recipients. The Journal of Heart and Lung Transplantation 16(8): 787–794

    Google Scholar 

  • WFED – [online] (13 February 1998) URL: http://www.wfed.org. Homepage of World Foundation for Environment and Development

  • WWF Norway (1998) Soppen fra Hardangervidda. Verdens Natur 2

Download references

Author information

Authors and Affiliations

  1. Centre for Development and the Environment, University of Oslo, PO Box 1116, Blindern, N-0317, Oslo, Norway

    Hanne Svarstad

  2. Department of Public and International Law, University of Oslo, PO Box 1116, Blindern, N-0317, Oslo, Norway

    Hans Chr. Bugge

  3. Department of Biology and Nature Conservation, Agricultural University of Norway &, Norway

    Shivcharn S. Dhillion

  4. Centre for Development and the Environment, University of Oslo, PO Box 1116, Blindern, N-0317, Oslo, Norway

    Shivcharn S. Dhillion

Authors
  1. Hanne Svarstad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Chr. Bugge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shivcharn S. Dhillion
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Svarstad, H., Bugge, H.C. & Dhillion, S.S. From Norway to Novartis: cyclosporin from Tolypocladium inflatum in an open access bioprospecting regime. Biodiversity and Conservation 9, 1521–1541 (2000). https://doi.org/10.1023/A:1008990919682

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008990919682

Search

Navigation